191931-56-3
Chemical Structure
NTNCB hydrochloride
- CAS No.: 191931-56-3
- Formula:C25H34ClN3O4S
- Molecular Weight:508.07
IUPAC Name: 2-nitro-N-(((1r,4r)-4-((((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)amino)methyl)cyclohexyl)methyl)benzenesulfonamide hydrochloride
InChIKey: BKCQHNDMUNWNQC-GEIALWGYSA-N
SMILES: O=S(C1=CC=CC=C1[N+]([O-])=O)(NC[C@H]2CC[C@H](CNCC3CC4=C(C=CC=C4)CC3)CC2)=O.[H]Cl
Biological Activity: NTNCB hydrochloride is a selective neuropeptide Y Y5 (NPY Y5) receptor antagonist with a Ki value of 8 nM for human Y5. NTNCB hydrochloride inhibits the proliferation and metastasis of cancer cells, suppresses xenograft tumor growth in vivo, and induces apoptosis in cancer cells. NTNCB hydrochloride inhibits microglial viability and reverses AURKA, CDC20, CDK1, and EZH2 as well as several cancer-overexpressed genes in cancer cells. NTNCB hydrochloride can be used in research on castration-resistant prostate cancer, non-small cell lung cancer, and obesity[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NTNCB hydrochloride | 98.36% | NTNCB hydrochloride is a selective neuropeptide Y Y5 (NPY Y5) receptor antagonist with a Ki value of 8 nM for human Y5. NTNCB hydrochloride inhibits the proliferation and metastasis of cancer cells, suppresses xenograft tumor growth in vivo, and induces apoptosis in cancer cells. NTNCB hydrochloride inhibits microglial viability and reverses AURKA, CDC20, CDK1, and EZH2 as well as several cancer-overexpressed genes in cancer cells. NTNCB hydrochloride can be used in research on castration-resistant prostate cancer, non-small cell lung cancer, and obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tian S, et al. GSFM: A genome-scale functional module transformation to represent drug efficacy for drug discovery. Acta pharmaceutica Sinica. B. 2025 Jan;15(1):133-150. [Content Brief]
- [2]. Bao N, et al. Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages. Molecular neurobiology. 2025 Apr;62(4):4724-4742. [Content Brief]
- [3]. Erkin ÖC, et al. Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer. Bioinformatics and biology insights. 2022;16:11779322221088796. [Content Brief]
- [4]. Islam I, et al. Discovery of potent and selective small molecule NPY Y5 receptor antagonists. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1767-9. [Content Brief]
